Vestal Point Capital LP Makes New $666,000 Investment in Traws Pharma, Inc. (NASDAQ:TRAW)

Vestal Point Capital LP purchased a new stake in shares of Traws Pharma, Inc. (NASDAQ:TRAW) in the 4th quarter, HoldingsChannel reports. The institutional investor purchased 75,000 shares of the company’s stock, valued at approximately $666,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Millennium Management LLC acquired a new position in shares of Traws Pharma during the fourth quarter valued at $89,000. Renaissance Technologies LLC acquired a new position in shares of Traws Pharma during the fourth quarter valued at $89,000. Geode Capital Management LLC acquired a new position in shares of Traws Pharma during the fourth quarter valued at $185,000. Boothbay Fund Management LLC acquired a new position in shares of Traws Pharma during the fourth quarter valued at $252,000. Finally, Alyeska Investment Group L.P. acquired a new position in shares of Traws Pharma during the fourth quarter valued at $1,036,000. Institutional investors and hedge funds own 7.95% of the company’s stock.

Traws Pharma Stock Performance

Shares of TRAW opened at $1.19 on Monday. Traws Pharma, Inc. has a 1 year low of $0.97 and a 1 year high of $19.44. The company has a market cap of $6.35 million, a price-to-earnings ratio of -0.01 and a beta of 1.59. The firm has a fifty day moving average of $1.95 and a 200-day moving average of $4.60.

Traws Pharma (NASDAQ:TRAW) last announced its quarterly earnings results on Wednesday, May 21st. The company reported $2.09 earnings per share (EPS) for the quarter, beating the consensus estimate of ($8.04) by $10.13. The firm had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.06 million.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.